Eisuke Murakami

3.9k total citations
102 papers, 2.1k citations indexed

About

Eisuke Murakami is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Eisuke Murakami has authored 102 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Hepatology, 57 papers in Epidemiology and 19 papers in Infectious Diseases. Recurrent topics in Eisuke Murakami's work include Hepatitis C virus research (45 papers), Liver Disease Diagnosis and Treatment (43 papers) and Hepatocellular Carcinoma Treatment and Prognosis (28 papers). Eisuke Murakami is often cited by papers focused on Hepatitis C virus research (45 papers), Liver Disease Diagnosis and Treatment (43 papers) and Hepatocellular Carcinoma Treatment and Prognosis (28 papers). Eisuke Murakami collaborates with scholars based in Japan, United States and Switzerland. Eisuke Murakami's co-authors include Kazuaki Chayama, Michio Imamura, Michael J. Sofia, Phillip A. Furman, Hiroshi Aikata, Masataka Tsuge, Michaël Otto, Tomokazu Kawaoka, Angela M. Lam and Haiying Bao and has published in prestigious journals such as Science, Journal of Biological Chemistry and Nature Medicine.

In The Last Decade

Eisuke Murakami

92 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eisuke Murakami Japan 25 1.3k 1.1k 658 459 188 102 2.1k
Jun Inoue Japan 28 1.3k 1.0× 1.0k 0.9× 557 0.8× 531 1.2× 214 1.1× 136 2.4k
Christoph Welsch Germany 23 1.5k 1.2× 1.2k 1.2× 431 0.7× 385 0.8× 67 0.4× 89 2.1k
Masaya Sugiyama Japan 33 2.2k 1.7× 2.5k 2.3× 450 0.7× 631 1.4× 271 1.4× 163 3.7k
Shinya Maekawa Japan 28 1.2k 0.9× 950 0.9× 257 0.4× 666 1.5× 362 1.9× 116 2.7k
Anita Kohli United States 24 1.2k 0.9× 1.5k 1.4× 304 0.5× 249 0.5× 216 1.1× 77 2.2k
Min Gao China 19 1.2k 0.9× 992 0.9× 530 0.8× 280 0.6× 163 0.9× 50 1.8k
Masahiko Kaito Japan 29 1.3k 1.0× 1.5k 1.4× 228 0.3× 539 1.2× 242 1.3× 85 2.8k
Hans Dieter Nischalke Germany 32 1.4k 1.1× 1.3k 1.2× 222 0.3× 322 0.7× 254 1.4× 91 2.8k
Ono S Brazil 21 1.2k 1.0× 1.2k 1.1× 309 0.5× 219 0.5× 117 0.6× 101 1.7k
Christian M. Lange Germany 24 1.1k 0.9× 969 0.9× 197 0.3× 420 0.9× 106 0.6× 86 2.0k

Countries citing papers authored by Eisuke Murakami

Since Specialization
Citations

This map shows the geographic impact of Eisuke Murakami's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eisuke Murakami with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eisuke Murakami more than expected).

Fields of papers citing papers by Eisuke Murakami

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eisuke Murakami. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eisuke Murakami. The network helps show where Eisuke Murakami may publish in the future.

Co-authorship network of co-authors of Eisuke Murakami

This figure shows the co-authorship network connecting the top 25 collaborators of Eisuke Murakami. A scholar is included among the top collaborators of Eisuke Murakami based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eisuke Murakami. Eisuke Murakami is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kawaoka, Tomokazu, Eisuke Murakami, Takanori Taogoshi, et al.. (2025). Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease. Journal of Pharmaceutical Health Care and Sciences. 11(1). 74–74.
2.
Fujino, Hatsue, Masataka Tsuge, Yasutoshi Fujii, et al.. (2025). Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B. Journal of Gastroenterology. 60(4). 469–478.
3.
Ono, Atsushi, C. Nelson Hayes, Ryoichi Miura, et al.. (2025). Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development. Journal of Proteome Research. 24(3). 1102–1117.
4.
Tsuboi, Akiyoshi, Hidenori Tanaka, Ken Yamashita, et al.. (2024). Predictive factors of portal hypertensive enteropathy exacerbations based on long-term outcomes. BMC Gastroenterology. 24(1). 287–287.
5.
6.
7.
Fujii, Yasutoshi, Tomokazu Kawaoka, Ryoichi Miura, et al.. (2024). First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Oncology. 103(8). 742–747. 3 indexed citations
8.
Bao, Hongmei, Masataka Tsuge, Takuro Uchida, et al.. (2024). Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver. Viruses. 16(11). 1743–1743. 1 indexed citations
9.
Fujii, Yasutoshi, Atsushi Ono, C. Nelson Hayes, et al.. (2024). Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma. Cancers. 16(7). 1328–1328. 3 indexed citations
10.
Fujino, Hatsue, Yasutoshi Fujii, Shinsuke Uchikawa, et al.. (2024). Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs. Hepatology Research. 54(11). 981–992. 1 indexed citations
11.
Uchikawa, Shinsuke, Tomokazu Kawaoka, Ryoichi Miura, et al.. (2024). Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single‐institution study. Hepatology Research. 55(2). 283–290. 1 indexed citations
12.
Uchida, Takuro, Masataka Tsuge, Eisuke Murakami, et al.. (2023). Acute liver injury in a non-alcoholic fatty liver disease patient with chloroform exposure: a case report. Clinical Journal of Gastroenterology. 16(2). 250–253. 2 indexed citations
13.
Nakahara, Takashi, Masafumi Ono, Takumi Kawaguchi, et al.. (2021). Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. Journal of Gastroenterology and Hepatology. 37(3). 592–599. 5 indexed citations
14.
Uchikawa, Shinsuke, Tomokazu Kawaoka, Yuwa Ando, et al.. (2020). Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. Oncology. 98(10). 727–733. 7 indexed citations
15.
Kodama, Kenichiro, Tomokazu Kawaoka, Shinsuke Uchikawa, et al.. (2019). Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. Oncology. 97(2). 75–81. 32 indexed citations
16.
Fujino, Hatsue, Mio Tanaka, Michio Imamura, et al.. (2019). Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. BMC Gastroenterology. 19(1). 169–169. 15 indexed citations
17.
Uchikawa, Shinsuke, Tomokazu Kawaoka, Kenichiro Kodama, et al.. (2019). Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer. 9(2). 148–155. 29 indexed citations
18.
Ohya, Kazuki, Michio Imamura, Yuji Teraoka, et al.. (2019). Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. Clinical Journal of Gastroenterology. 13(2). 267–270. 3 indexed citations
19.
Appleby, T.C., Jason K. Perry, Eisuke Murakami, et al.. (2015). Structural basis for RNA replication by the hepatitis C virus polymerase. Science. 347(6223). 771–775. 254 indexed citations
20.
Aikata, Hiroshi, Tomokazu Kawaoka, Eisuke Murakami, et al.. (2011). A case report of perforation of the colon during the sorafenib therapy for hepatocellular carcinoma. Kanzo. 52(12). 777–783.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jun Inoue Breakdown of academic impact, for papers by Christoph Welsch Breakdown of academic impact, for papers by Masaya Sugiyama Breakdown of academic impact, for papers by Shinya Maekawa Breakdown of academic impact, for papers by Anita Kohli Breakdown of academic impact, for papers by Min Gao Breakdown of academic impact, for papers by Masahiko Kaito Breakdown of academic impact, for papers by Hans Dieter Nischalke Breakdown of academic impact, for papers by Ono S Breakdown of academic impact, for papers by Christian M. Lange
Rankless by CCL
2026